---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012783"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2024-09-13T23:59:59+00:00"
generated_at: "2026-05-31T04:52:58.660525+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coherus warns of temporary UDENYCA supply interruption due to packaging CMO constraints

## Summary
- Third-party CMO over-commitments cause labeling/packaging delay; API and drug product unaffected.
- Channel supply projected depleted by mid-Oct; manufacturing to resume mid-Oct, product availability early Nov.
- Company secures second packaging CMO; commercial supply expected Q1 2025, more than doubling capacity.
- Since 2021, invested >$30M across supply chain; expects UDENYCA production cost to drop ~1/3 from current levels.
- Reaffirms combined 2024 R&D and SG&A expense guidance of $250-265M, including ~$40M stock-based compensation.

## SEC filing metadata
- accession: 0001558370-24-012783
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2024-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837024012783/0001558370-24-012783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837024012783/chrs-20240913x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012783
- JSON: https://secwatch.observer/filing/0001558370-24-012783.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012783.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.